BeiGene (NASDAQ:BGNE) is a clinical-stage biopharma company focused on the discovery and development of best-in-class, targeted drugs for the treatment of cancer.
BeiGene (Beijing) Co., Ltd
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/beigene” connections=”true” suffix=””]
In 2011, Janssen out-licensed development and commercialization rights of Intetumumab/CNTO-95 & MTKi/BGB102 to BeiGene Ltd, for Australia, China, Hong Kong, New Zealand, Korea, Singapore and Taiwan Region. In 2013, Merck Serono acquired worldwide development and marketing rights (excluding China) of BGB-290 and BGB-283 form the BeiGene.
In Mar 3015, BeiGene partnered with Sigma-Aldrich for its SAFCë Commercial custom drug manufacturing services. In Aug 2013, BeiGene entered into a collaboration agreement with GENEWIZ, Inc. to accelerate cancer biomarker discovery.
In Feb 2016, BeiGene completed IPO offering in the U.S., raising around US$182 Mn. In May 2015, BeiGene raised around RMB600 Mn (US$97 Mn) co-led by Hillhouse Capital, with participation from CITIC Private Equity and other investors.
In Nov. 2014, BeiGene raised 450 Mn RMB (aprox. $75 Mn USD). The major investors includes Hillhouse Capital and CITIC PE, as well as an undisclosed U.S. public investment fund specializing in life sciences.